GENE ONLINE|News &
Opinion
Blog

Ovarian Cancer
AbbVie Invests $10.1 Billion in ImmunoGen, Targeting the Ovarian Cancer Landscape
2023-12-05
Deceptive Health Advice on TikTok Raises Concerns About Gynecologic Cancer Misinformation
2023-09-20
Deep Into Bankruptcy Proceedings, Clovis Sells Cancer Med Rubraca
2023-04-10
Johnson & Johnson to Pay $8.9 Billion Over 25 Years to Settle Talcum Powder Lawsuits
2023-04-06
J&J’s Market Value Plummets by $17 Billion After Appeals Court Denies Bankruptcy Escape
2023-01-31
ImmunoGen Wins FDA Accelerated Approval For Ovarian Cancer Drug
2022-11-16
EMA Recommends Restriction on Rubraca
2022-07-25
Lynparza Bags Multiple Approvals in Japan
2021-01-05
FMI’s Liquid Biopsy Test Adds 3 Companion Diagnostic Indications for Advanced Ovarian, Breast and Lung Cancers
2020-10-30
Korean Biotech, AbClon Enters Trials with New CAR-T Molecule against Ovarian Cancer
2020-04-23
Lynparza Meets Primary Endpoint in Phase III PROfound Trial
2019-08-16
First PARP inhibitor approved for 1L maintenance therapy of BRCAm advanced ovarian cancer
2018-12-28
LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
EVENT
Scroll to Top